BOSTON, Mass.--(BUSINESS WIRE)--May 15, 2005--Oxxon Therapeutics, Inc. (Oxxon) today reported interim data from its ongoing Phase II MEL1 immunotherapy study in patients with advanced melanoma. The Company presented the data during a poster session at the American Society for Clinical Oncology (ASCO) annual meeting held in Orlando, Florida. Oxxon’s MEL1 immunotherapy delivers multiple melanoma specific epitopes through the Company’s proprietary PrimeBoost approach. In this study, patients received increasing priming doses of plasmid DNA that were then boosted with increasing doses of Modified Vaccinia Ankara (MVA) containing the same epitopes. The MVA doses included the highest administered dose yet in human studies (at 1 x 10e9pfu). The 16-week interim results of the 52-week trial demonstrated that MEL1 was safe and well tolerated, with injection site reactions following first MVA immunization reported as the most common side effect. These reactions were not dose limiting.
